An exploratory study of circulating cell-free mRNAs across colorectal cancer stages
Abstract
This study evaluated circulating mRNAs (B2M, TIMP-1, CLU, SERPINE1, GAL3, and S100A9) as potential biomarkers for colorectal cancer (CRC). Plasma levels were measured in CRC patients (stages I–IV, n = 178) and healthy individuals (HIs, n = 171). B2M, TIMP-1, CLU, and S100A9 mRNA levels were significantly elevated in CRC patients vs. HIs. B2M differed only in stage IV, while TIMP-1, CLU, and S100A9 showed significance across all stages except I. A composite index, I-BTC, was developed using B2M, TIMP-1, and CLU via logistic regression. I-BTC improved discrimination between HIs and CRC patients, even at stage I (p = 0.001), with stronger significance in later stages (p ≤ 0.0001). These results validate analytical robustness of the method and highlight its diagnostic potential including for early-stage CRC through spe- cific mRNAs combinations.
Related
- Lower circulating angiotensinogen levels across ACLD stages are associated with hepatic dysfunction and mortality
- Circulating Immune-Related Biomarkers in Egyptian Women with Early Breast Cancer: An Exploratory Case–Control Study Across IHC-Defined Clinicopathological Subgroups
- Understanding consumption patterns of sugar-sweetened beverages across stages of adolescence in Mumbai city, India: an exploratory cross-sectional study for insights to develop innovative sugar reduction strategies
- Exploratory Analysis of Circulating miR‐486‐3p and miR‐21‐5p in Early Detection and Subtype Classification of Luminal A and B Breast Cancer in Peruvian Women
- Circulating Tumor DNA (ctDNA) for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRC): Current Evidence, Clinical Applications, and Future Directions.
BibTeX
@article{mazard2026exploratory,
title = {{An exploratory study of circulating cell-free mRNAs across colorectal cancer stages}},
author = {Thibault Mazard and Marie Grosgeorges and Laura Veyrie and Simon Thezenas and Brice Pastor and Ekaterina Pisareva and Gérald Lossaint and Evelyne Lopez-Crapez and Marc Ychou and Alain R Thierry and Corinne Prévostel and Philippe Blache},
journal = {iScience},
year = {2026},
month = jul,
doi = {10.1016/j.isci.2026.116398},
url = {https://hal.science/hal-05740964v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - An exploratory study of circulating cell-free mRNAs across colorectal cancer stages
AU - Thibault Mazard
AU - Marie Grosgeorges
AU - Laura Veyrie
AU - Simon Thezenas
AU - Brice Pastor
AU - Ekaterina Pisareva
AU - Gérald Lossaint
AU - Evelyne Lopez-Crapez
AU - Marc Ychou
AU - Alain R Thierry
AU - Corinne Prévostel
AU - Philippe Blache
PY - 2026
DA - 2026/07/17
JO - iScience
DO - 10.1016/j.isci.2026.116398
UR - https://hal.science/hal-05740964v1
AB - This study evaluated circulating mRNAs (B2M, TIMP-1, CLU, SERPINE1, GAL3, and S100A9) as potential biomarkers for colorectal cancer (CRC). Plasma levels were measured in CRC patients (stages I–IV, n = 178) and healthy individuals (HIs, n = 171). B2M, TIMP-1, CLU, and S100A9 mRNA levels were significantly elevated in CRC patients vs. HIs. B2M differed only in stage IV, while TIMP-1, CLU, and S100A9 showed significance across all stages except I. A composite index, I-BTC, was developed using B2M, TIMP-1, and CLU via logistic regression. I-BTC improved discrimination between HIs and CRC patients, even at stage I (p = 0.001), with stronger significance in later stages (p ≤ 0.0001). These results validate analytical robustness of the method and highlight its diagnostic potential including for early-stage CRC through spe- cific mRNAs combinations.
SN - 2589-0042
ER -